试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, non-randomized, open-label
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •ECOG performance status: <= 1
- •Patients with 3 months or longer life expectancy
排除标准
- •Patients who received other investigational drug or immune checkpoint inhibitor within 28 days prior to enrollment
- •Patients who received anti-cancer drug within 14 days prior to enrollment
结局指标
主要结局
-
safety - Dose limiting toxicity - Adverse event
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I study of CBA-1205JPRN-jRCT2080225288Chiome Bioscience Inc.41
招募中
不适用
Phase I study of CBA-1535jRCT2031210708Chiome Bioscience Inc.70
招募中
1 期
Phase I study of CBA-1535JPRN-jRCT2031210708Tanaka Miseri70
进行中（未招募）
1 期
Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancerSubjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease.MedDRA version: 14.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004155-39-FRBayer Healthcare AG60
进行中（未招募）
1 期
A Phase II uncontrolled study of BAY 73-4506 in previously untreated patients with metastatic or unresectable renal cell cancer (RCC)Renal Cell CarcinomaMedDRA version: 20.0Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864EUCTR2008-000107-28-GBBayer HealthCare Pharmaceuticals Inc49